Browse the evidence

Bariatric surgery (RYGB and VSG) is more effective than intensive medical/lifestyle therapy for the resolution of type 2 diabetes, often occurring prior to significant weight loss.

If you have Type 2 Diabetes, surgery (RYGB or VSG) is significantly more effective at resolving the disease than medication and lifestyle changes alone. Resolution can happen even before significant weight loss. Patients with shorter diabetes duration and higher pre-op C-peptide levels have the best chance of resolution.

Weekly subcutaneous semaglutide (up to 1 mg) as an adjunct to automated insulin delivery significantly improves glycemic control (increasing time in range by 4.8 percentage points) and reduces body weight in adults with type 1 diabetes without increasing hypoglycemia risk.

If you have Type 1 Diabetes and use an automated insulin delivery system, adding weekly semaglutide (up to 1 mg) can significantly improve your time in range and help with weight loss without increasing the risk of low blood sugar. While gastrointestinal side effects are common, they are usually manageable, and the risk of ketosis, though present, can be mitigated with education and monitoring. This is a viable option, especially for those with higher BMI.

Tirzepatide significantly reduces body weight and improves lipid profiles (lowering LDL-C and triglycerides, raising HDL-C) in patients with T2DM and obesity.

Tirzepatide is a once-weekly injection that significantly reduces body weight and improves lipid profiles (lowering bad cholesterol and triglycerides, raising good cholesterol) in patients with T2DM and obesity. The benefits are dose-dependent.

Dual incretin agonists (GLP-1R/GIPR) such as tirzepatide offer superior weight loss and glycemic control compared to GLP-1 mono-agonists, with a safety profile comparable to mono-agonists.

Tirzepatide, a once-weekly injection targeting both GLP-1 and GIP receptors, has demonstrated significant weight loss (up to 22.5%) and improved blood sugar control in Phase 3 trials. Importantly, its side effect profile is similar to existing GLP-1 drugs, making it a highly effective option for managing obesity and type 2 diabetes.

Semaglutide 2.4 mg weekly induces mean weight loss of ~15% and enables >20% weight loss in significant patient subsets, significantly outperforming older anti-obesity medications and lifestyle interventions alone.

Semaglutide 2.4 mg, taken once weekly, is a highly effective treatment for obesity, producing an average 15% body weight loss over 68 weeks when combined with lifestyle changes. It significantly outperforms older medications and lifestyle interventions alone, helping to overcome the biological drive to regain weight. This treatment is suitable for adults with a BMI of 30 or higher, or 27 or higher with comorbidities, and requires a gradual dose escalation to manage side effects.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior glycemic control and weight loss compared to GLP-1 receptor analogues (semaglutide, dulaglutide) in patients with type 2 diabetes.

For patients with Type 2 Diabetes seeking significant weight loss and glucose control, tirzepatide offers superior efficacy compared to existing GLP-1 analogues like semaglutide. It is administered as a once-weekly injection, starting at 5mg and titrating up to 15mg, combined with diet and exercise.

Tirzepatide 15 mg and semaglutide 1.0 mg, when added to metformin in type 2 diabetes, provide superior HbA1c reduction and weight loss compared to other GLP-1 receptor agonists, without increasing hypoglycemia risk.

For patients with Type 2 Diabetes on Metformin, Tirzepatide 15mg and Semaglutide 1.0mg are the most effective options for lowering blood sugar and losing weight among GLP-1 agonists. They do not increase hypoglycemia risk. If injections are a barrier, oral Semaglutide 14mg is a viable alternative with good efficacy.

GLP-1 receptor agonists (GLP-1-RAs) produce significant weight loss (up to 14.9%) and improved glycemic control (HbA1c reduction 0.8-1.8%) in adults with obesity or type 2 diabetes through mechanisms involving delayed gastric emptying, increased satiety, and glucose-dependent insulin secretion.

If you have obesity or type 2 diabetes and lifestyle changes haven't been enough, GLP-1 medications like semaglutide or liraglutide are highly effective. They work by mimicking a hormone that tells your brain you're full and slows down digestion. Expect some stomach upset at first, but starting with a low dose and increasing slowly helps. These drugs can lead to significant weight loss (around 15% in some cases) and better blood sugar control, especially if you have heart disease risk factors.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significant, dose-dependent weight loss in adults with obesity (BMI ≥30 or ≥27 with comorbidities) and type 2 diabetes, outperforming placebo, semaglutide, and insulin glargine.

Tirzepatide is a once-weekly injectable medication for obesity and type 2 diabetes that works by mimicking two gut hormones (GIP and GLP-1). It significantly reduces body weight (up to ~21% in clinical trials) and improves blood sugar control. It is more effective than semaglutide and insulin glargine for weight loss. Common side effects include nausea and diarrhea, which usually improve over time. It requires a prescription and medical supervision.

Treatment with GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and liraglutide produces substantial body weight loss (exceeding 15%) and improves glucose control, leading to type 2 diabetes prevention and possible disease remission.

If you have obesity or type 2 diabetes, GLP-1 receptor agonists (like semaglutide or liraglutide) are highly effective treatments that can help you lose more than 15% of your body weight and improve blood sugar control. This can potentially lead to remission of type 2 diabetes. While lifestyle changes are important, they are often not enough on their own to maintain weight loss or prevent diabetes progression, making these medications a key part of modern management.

Semaglutide (2.4 mg subcutaneous once weekly) produces significant weight loss in adults with obesity or overweight by reducing appetite and energy intake rather than increasing energy expenditure.

Semaglutide 2.4 mg injected once weekly, combined with lifestyle changes, leads to substantial weight loss (approx 15%) in adults with obesity. The primary mechanism is reduced appetite and food cravings, not increased metabolism. Be prepared for potential nausea, which is the most common reason people stop treatment.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, induces greater weight loss and improves glycemic control more effectively than GLP-1 RAs alone.

Tirzepatide (5-15 mg weekly) combines GIP and GLP-1 mechanisms to achieve higher weight loss (up to 21%) than GLP-1 drugs alone. It is a potent option for those who need maximum efficacy.

GLP-1 receptor agonists (semaglutide 2.4 mg, tirzepatide) produce significantly greater weight loss than older pharmacotherapies (liraglutide, orlistat, phentermine/topiramate) and provide cardiovascular benefits.

If lifestyle changes alone are insufficient, newer GLP-1 medications like semaglutide (2.4 mg weekly) offer significantly higher weight loss (approx. 15%) compared to older drugs. Discuss these options with your doctor, keeping in mind that cost and insurance coverage may be barriers.

Incretin-based therapies (liraglutide, semaglutide, tirzepatide) produce significant body weight reduction (≥5% in majority of patients) and reduce the 10-year relative risk of type 2 diabetes development by 60-69% in individuals with obesity.

If you have obesity or overweight with related health issues, incretin-based medications (like semaglutide or tirzepatide) are highly effective for significant weight loss and preventing type 2 diabetes. They work by mimicking hormones that regulate appetite and are taken weekly (or daily for liraglutide) alongside lifestyle changes. These are not quick fixes but long-term treatments requiring continuous use to maintain results.

Tirzepatide demonstrates superior body weight reduction compared to semaglutide 2.4 mg and liraglutide 3.0 mg in non-diabetic subjects with obesity.

Among incretin therapies, tirzepatide offers the greatest weight loss potential for non-diabetic individuals with obesity, outperforming semaglutide and liraglutide.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior body weight reduction and glycemic control compared to semaglutide, insulin degludec, and insulin glargine in patients with type 2 diabetes.

For patients with Type 2 Diabetes struggling with weight and blood sugar, Tirzepatide offers a once-weekly injection that has been shown to be more effective than semaglutide, insulin degludec, and insulin glargine in reducing both body weight and HbA1c. Treatment starts at a low dose (2.5 mg) and is titrated up to 5, 10, or 15 mg weekly to manage side effects. This therapy is particularly beneficial for those who have not achieved targets with oral medications or other injectables.

Tirzepatide promotes significant body weight loss in non-diabetic adults with obesity, with efficacy increasing with dose (5, 10, 15 mg).

For individuals with obesity who do not have Type 2 Diabetes, Tirzepatide is an approved once-weekly injection that has been shown to produce significant and clinically meaningful weight loss over 72 weeks. The medication is titrated starting at 2.5 mg and increased to 5, 10, or 15 mg weekly. It also improves blood pressure, waist circumference, and lipid profiles.

Subcutaneous semaglutide (0.5 mg and 1.0 mg) significantly reduces HbA1c and body weight in Type 2 Diabetes patients compared to placebo and other antidiabetic agents.

If you have Type 2 Diabetes, once-weekly subcutaneous semaglutide (0.5 mg or 1.0 mg) is a highly effective treatment for lowering blood sugar (HbA1c) and reducing body weight. It works better than many other standard diabetes medications and placebo. Be prepared for potential nausea or diarrhea, which are common but often mild and decrease over time.

Semaglutide (2.4 mg once-weekly subcutaneous) significantly reduces body weight in adults with obesity or overweight with comorbidities compared to placebo.

For adults with obesity or overweight who have at least one weight-related health issue (like high blood pressure or cholesterol), a once-weekly injection of semaglutide (2.4 mg) combined with lifestyle changes can lead to significant, sustained weight loss (averaging nearly 15% of body weight in trials). While gastrointestinal side effects like nausea are common, they often subside, and starting with a lower dose can help your body adjust.

Semaglutide (0.5-1.0 mg once-weekly subcutaneous) lowers HbA1c and reduces body weight more effectively than other common GLP-1 RAs (exenatide, dulaglutide, liraglutide) and SGLT-2 inhibitors (canagliflozin) in Type 2 Diabetes.

If you have Type 2 Diabetes, semaglutide (0.5-1.0 mg weekly) is a highly effective option that lowers blood sugar and promotes weight loss more effectively than several other common diabetes medications like exenatide, dulaglutide, or liraglutide. It can be used alone or combined with other drugs like metformin or insulin.

Semaglutide (2.4 mg/weekly) significantly reduces the risk of major adverse cardiovascular events (MACE) in patients with overweight or obesity without diabetes, while also producing substantial weight loss and improving heart failure symptoms in those with preserved ejection fraction.

If you have heart disease or high risk for it, along with excess weight, semaglutide (Ozempic/Wegovy) is a highly effective treatment. It is taken as a once-weekly injection, starting at a low dose and increasing over 4 months to 2.4 mg. It significantly lowers your risk of heart attack and stroke, helps you lose about 9-13% of your body weight, and improves heart failure symptoms if you have them. Common side effects like nausea are usually temporary and manageable.

Tirzepatide (5-15 mg weekly) significantly reduces body weight and HbA1c in patients with Type 2 Diabetes and obesity, outperforming semaglutide, insulin degludec, and insulin glargine.

Tirzepatide is a once-weekly injection for T2DM and obesity that works by mimicking gut hormones (GIP and GLP-1) to improve insulin sensitivity and reduce appetite. It produces greater weight loss and blood sugar control than existing GLP-1 drugs like semaglutide or insulin. Start with a low dose to manage side effects, titrating up every few weeks.

High-dose GLP-1 receptor agonists (semaglutide 2.4 mg/week) and dual GLP-1/GIP agonists (tirzepatide 15 mg/week) produce substantial weight loss (>15% and >20% respectively) in non-diabetic obese individuals, with efficacy maintained over 2 years.

For non-diabetic individuals with obesity, weekly injections of semaglutide (2.4 mg) or tirzepatide (15 mg), combined with a reduced-calorie diet and exercise, can lead to 15-20% body weight loss over two years. Expect initial gastrointestinal side effects like nausea, which usually subside within a few months as the dose is gradually increased.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide produce significant weight loss and improve cardiovascular outcomes by acting as incretin mimetics that target G-protein-coupled receptors to regulate body fat and energy balance.

GLP-1 medications like semaglutide are highly effective for significant weight loss (approx. 15%) when combined with a reduced-calorie diet. They work by mimicking gut hormones to reduce appetite and slow digestion. Treatment requires weekly injections and gradual dose escalation to manage side effects like nausea. Because obesity is chronic, long-term use is often necessary to maintain results.